Ensign Peak Advisors’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History

Ensign Peak Advisors’s Portfolio GRTX Stock Details GRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-151,777	Closed	-$474K	–	1772
2023 Q2	$474K	Hold	151,777	–	–	﹤0.01%	1646
2023 Q1	$389K	Hold	151,777	–	–	﹤0.01%	1682
2022 Q4	$226K	Hold	151,777	–	–	﹤0.01%	1739
2022 Q3	$264K	Hold	151,777	–	–	﹤0.01%	1763
2022 Q2	$197K	Buy	151,777 +112,002	+282%	+$192K	﹤0.01%	1796
2022 Q1	$95K	Hold	39,775	–	–	﹤0.01%	2042
2021 Q4	$153K	Buy	+39,775	New	+$132K	﹤0.01%	1980
2021 Q1	–	Sell	-7,128	Closed	-$73K	–	1894
2020 Q4	$73K	Hold	7,128	–	–	﹤0.01%	1797
2020 Q3	$64K	Sell	7,128 -1,797	-20%	-$14.2K	﹤0.01%	1720
2020 Q2	$64K	Hold	8,925	–	–	﹤0.01%	1654
2020 Q1	$85K	Sell	8,925 -16,075	-64%	-$207K	﹤0.01%	1584
2019 Q4	$329K	Buy	+25,000	New	+$305K	﹤0.01%	1582

Other funds holding GRTX

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NFGH

Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Ensign Peak Advisors's GRTX Position: Q3 2023 in Review

Ensign Peak Advisors sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q3 2023, closing a stake of 151,777 shares — an estimated $474K sold.

Ensign Peak Advisors first reported a position in GRTX in Q4 2019 and held it in 12 quarters. The position peaked at $474K in Q2 2023. 38 funds tracked by Wall St. Rank hold GRTX as of Q3 2023.

Ensign Peak Advisors reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Ensign Peak Advisors sold 151,777 Galera Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $474K.
Ensign Peak Advisors first reported a position in Galera Therapeutics, Inc. Common Stock in Q4 2019 and held it in 12 quarters.
Ensign Peak Advisors's Galera Therapeutics, Inc. Common Stock position peaked at $474K in Q2 2023.
38 funds tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Ensign Peak Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.